Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Investigating the siRNA approaches to Alpha-1 Antitrypsin Deficiency Liver Disease from Arrowhead and Alnylam

Ticker(s): ARWR, ALNY

Who's the expert?

Name: Dr Zahida Khan - MD |PhD

Institution: University of Pittsburgh

  • Pediatric transplant hepatologist and Assistant Professor of Pediatrics and Pathology at the UPMC Children’s Hospital of Pittsburgh.
  • Currently manages 30 patients with Alpha-1 Antitrypsin Deficiency.
  • Research investigates critical cellular pathways for liver regeneration, mechanisms of hepatocyte regeneration in alpha-1 antitrypsin deficiency, and cellular and molecular therapies for liver-based metabolic diseases.

Interview Goal
To discuss the market potential of ARC-AAT from Arrowhead and ALN-AAT02 from Alnylam in treating Alpha-1 Antitrypsin Deficiency Liver Disease.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.